

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 34D2043657	(X3) Date Survey Completed 11/20/2019
Name of Provider or Supplier Southern Oncology Specialists	Street Address, City, State 10320 Mallard Creek Road, Suite 100, Charlotte, NC	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on desk review of CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D and desk review of 2018 and 2019 API (American Proficiency Institute) proficiency testing results on 11/20/19, the laboratory failed to successfully participate in proficiency testing for White Blood Cell Differential. See the deficiency cited at D2130.
D2130	HEMATOLOGY CFR(s): 493.851(f)

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on desk review of CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D and desk review of 2018 and 2019 API (American Proficiency Institute) proficiency testing results on 11/20/19, the laboratory failed to achieve satisfactory performance for White Blood Cell Differential in three of four consecutive test events, resulting in unsuccessful performance. Findings: 1. Review of CMS Casper 155D revealed the laboratory received a score of 0% for White Blood Cell Differential on the 2018 2nd and the 2018 3rd Hematology events and received a score of 60% for White Blood Cell Differential on the 2019 2nd Hematology event. 2. Review of 2018 and 2019 API proficiency testing results revealed: a. The laboratory received a score of 0% for White Blood Cell Differential on the 2018 2nd and the 2018 3rd Hematology events. b. The laboratory received a score of 80% for granulocytes %, a score of 60% for lymphocytes %, and a score of 40% for monocytes %, resulting in a score of 60% for White Blood Cell Differential on the 2019 2nd Hematology event.

D6000

MODERATE COMPLEXITY LABORATORY DIRECTOR
CFR(s): 493.1403

The laboratory must have a director who meets the qualification requirements of 493.1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart.

This CONDITION is not met as evidenced by:

Based on desk review of CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D and desk review of 2018 and 2019 API (American Proficiency Institute) proficiency testing results on 11/20/19, the laboratory director failed to ensure successful participation in proficiency testing as required in Subpart H. See the deficiency cited at D6016.

D6016

LABORATORY DIRECTOR RESPONSIBILITIES
CFR(s): 493.1407(e)(4)(i)

The laboratory director is responsible for the overall operation and administration of the laboratory, including the employment of personnel who are competent to perform test procedures, and record and report test results promptly, accurate, and proficiently and for assuring compliance with the applicable regulations. (e) The laboratory director must-- (e)(4)(i) Ensure that the proficiency testing samples are tested as required under Subpart H of this part;

This STANDARD is not met as evidenced by:

Based on desk review of CMS (Centers for Medicare and Medicaid Services) Casper reports 153D and 155D and desk review of 2018 and 2019 API (American Proficiency Institute) proficiency testing results on 11/20/19, the laboratory director failed to ensure successful participation in proficiency testing as required in Subpart H. Findings: 1. Review of CMS Casper 155D revealed the laboratory received a score of 0% for White Blood Cell Differential on the 2018 2nd and the 2018 3rd

Hematology events and received a score of 60% for White Blood Cell Differential on the 2019 2nd Hematology event. 2. Review of 2018 and 2019 API proficiency testing results revealed: a. The laboratory received a score of 0% for White Blood Cell Differential on the 2018 2nd and the 2018 3rd Hematology events. b. The laboratory received a score of 80% for granulocytes %, a score of 60% for lymphocytes %, and a score of 40% for monocytes %, resulting in a score of 60% for White Blood Cell Differential on the 2019 2nd Hematology event.